Dominari Holdings Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of stockholders held on March 4, 2026. Dominari Holdings Inc. (formerly Akido Pharma, Inc.) is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol DOMH.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
A quorum of 7,019,711 voting shares (approximately 43.27% of eligible shares) was present at the Special Meeting. The following proposals were approved by a majority of votes cast:
- Proposal No. 1 (2022 Equity Incentive Plan Amendment): Approved to increase the number of shares reserved for issuance under the 2022 Plan by 10,000,000 shares, raising the total from 11,720,750 to 21,720,750 shares. The amendment also clarifies an automatic annual increase mechanism effective January 1, 2027, through January 1, 2032, equal to the lesser of 20% of outstanding shares or a board-determined amount.
- Proposal No. 2 (Adjournment): Approved to allow the adjournment of the Special Meeting if necessary to solicit further proxies.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard voting procedures. The primary operational impact is the expansion of the equity pool available for employee incentives.
Key Facts for Investor Verification
- Verify the total number of shares reserved for issuance under the 2022 Plan is now 21,720,750.
- Confirm the automatic annual increase provision for the equity plan commencing January 1, 2027.
- Review the full Proxy Statement filed on February 6, 2026, for detailed rationale behind the amendments.
- Note that the company previously operated as Akido Pharma, Inc.